|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 14.2 0.00 0.00%
Independent Chairman of the Board
Dr. Hakan Bjorklund, Ph.D. was Independent Chairman of the Board at Swedish Orphan Biovitrum AB since May 24, 2016. He is Chairman of Compensation Benefits Committee. He has an extensive international background in the life science industry, from both RD and sales and marketing. He has experience of leading healthcare companies in expansive development phases. He was CEO, Nycomed Member of the Board of Directors, Alere, Coloplast, Danisco, and Lundbeck and Board Member, Biovitrum 2001 2007. He is Industry Executive, Avista Capital Partners Member of the Board of Directors of Bonesupport, Acino and Trimb. He holds Ph.D., Karolinska Institutet, Stockholm, Sweden.
Age: 60 Chairman Since 2016 Ph.D
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 8.0 %
which means that it generated profit of $8.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 5.6 %
meaning that it generated $5.6 on every $100 dollars invested by stockholders.
The company has accumulated 53.55 M in total debt with debt to equity ratio (D/E) of 0.09 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.74 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.